INMB Share Price Performance
US$2.26
0.27 (13.57%)
67.7% undervalued intrinsic discount
US$7.00
Fair Value
Price US$2.26
AnalystConsensusTarget US$7.00
AnalystLowTarget US$4.00
AnalystHighTarget US$9.00
Fair ValueUS$7.00
Share Pricen/a
INmune Bio Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
INMB Community Narratives
AN
Fair Value
·Fair Value US$7 67.7% undervalued intrinsic discount
Neuroinflammation And Rare Disease Therapies Will Drive Long-Term Opportunity In Innate Immunity
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$4 43.5% undervalued intrinsic discount
Regulatory And Funding Risks Around Platform Therapies Will Eventually Support A Stronger Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$9 74.9% undervalued intrinsic discount
Rare Disease And Neuroinflammation Platforms Will Unlock Significant Long-Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
INmune Bio
67.7% undervalued intrinsic discount
Neuroinflammation And Rare Disease Therapies Will Drive Long-Term Opportunity In Innate Immunity
View narrativeAN
Updated 24 Jul
INmune Bio
74.9% undervalued intrinsic discount
Rare Disease And Neuroinflammation Platforms Will Unlock Significant Long-Term Upside Potential
View narrativeAN
Updated 10 Jul
INmune Bio
43.5% undervalued intrinsic discount
Regulatory And Funding Risks Around Platform Therapies Will Eventually Support A Stronger Outlook
View narrativeAN
Updated 26 Jun
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
INMB: UK Regulatory Progress And Cell Therapy Platform Will Drive Future Upside
Fair Value: US$7 67.7% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
INMB: Extended Cell Therapy Patent Protection Will Drive Future Upside Potential
Fair Value: US$9 74.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
INMB: Fast Track Alzheimer’s Program Will Drive Future Upside Potential
Fair Value: US$4 43.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
INmune Bio Inc. Key Details
About INMB
- Founded
- 2015
- Employees
- 21
- CEO
- WebsiteView website
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
